Brought to you by 
Sanofi bids to take the rest of Zentiva
19 Jun 2009
Executive Summary
In what could become a competitive bidding situation, Sanofi-Aventis has announced its offer to acquire the remaining 75% of Czech generic drug maker Zentiva that it does not already own for €43.42 per share, or about €1.24bn ($1.9bn). The offer comes on the heels of a bid proposed in May by Czech financial institution PPF, Zentiva's second largest shareholder (to Sanofi) for €39 per share. (Zentiva's board has recommended that shareholders not accept PPF's initial offer.)
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Acquisition
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com